These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 18471793)

  • 1. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME
    Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of androgen receptor in prostate cancer.
    Linja MJ; Visakorpi T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):255-64. PubMed ID: 15663988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of androgen receptor signaling in prostate cancer.
    Dehm SM; Tindall DJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):63-74. PubMed ID: 15757439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
    Agoulnik IU; Weigel NL
    J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
    D'Antonio JM; Ma C; Monzon FA; Pflug BR
    Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene amplifications associated with the development of hormone-resistant prostate cancer.
    Edwards J; Krishna NS; Witton CJ; Bartlett JM
    Clin Cancer Res; 2003 Nov; 9(14):5271-81. PubMed ID: 14614009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy.
    Lee EC; Tenniswood MP
    J Cell Biochem; 2004 Mar; 91(4):662-70. PubMed ID: 14991758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
    Wang G; Sadar MD
    J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression.
    Knudsen BS; Miranti CK
    J Cell Biochem; 2006 Oct; 99(2):345-61. PubMed ID: 16676354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormone-resistant epithelial cancer of the prostate].
    Medvedev VL
    Urologiia; 2001; (4):29-33. PubMed ID: 11569231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
    Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
    Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.